ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1490

High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis

Nuria Barbarroja1, Laura Cuesta-Lopez1, Carlos Pérez-Sánchez1, Ariana Barberá-Betancourt2, Ivan Arias-de la Rosa1, Miriam Ruiz-Ponce1, Clementina Lopez-Medina3, Ignacio Gómez-Garcia4, lourdes Ladehesa-Pineda5, Maria del Carmen Abalos-Aguilera6, Chary López-Pedrera7, Alejandro Escudero-Contreras1 and Eduardo Collantes1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2University of Cambridge, Cambridge, United Kingdom, 3Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, 4IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 5Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, 6Hospital Universitario Reina Sofia, Cordoba, Spain, 7Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain

Meeting: ACR Convergence 2022

Keywords: spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: A significant progress has recently been made in the identification of molecular profiles involved in the pathogenesis of chronic autoinflammatory diseases through the use of high throughput techniques such as massive RNA sequencing. To date, only few studies have been carried out in axial spondyloarthritis (axSpA), which would allow the identification of new therapeutic targets and disease biomarkers.Objectives: 1) To identify clusters of highly correlated genes enriched in biological functions and specific molecular pathways involved in the pathogenesis of axSpA. 2) To study the association between the molecular signatures identified and the clinical-analytical profile of the disease.

Methods: Cross-sectional study including 20 healthy donors and 105 axSpA patients from the CASTRO cohort who underwent an exhaustive clinical evaluation including disease activity and functional limitation, structural damage and spinal mobility. Additionally, analytical parameters were measured and the carotid intima media thickness was evaluated by carotid eco-doppler. Mononuclear cells were purified from peripheral blood, and RNA was isolated. RNA from 25 axSpA patients was sequenced using the Illumina platform. For the identification of patient subgroups and the generation of co-expressed gene modules, the “hierarchical clustering” and WGCNA (“Weight gene correlation network analysis”) methodologies were used, respectively. Functional analysis of the genes conforming each module was carried out to identify enriched pathways and functions using the EnrichR platform. Hub genes were measured through high throughput PCR (Fluidigm Biomark HD) in a validation cohort of 80 axSpA and 20 healthy donors. Association and correlation studies between the molecular and the clinical profiles were performed.

Results: Unsupervised analysis of the transcriptome revealed the presence of two “clusters” of axSpA patients, clearly differentiated by their molecular and clinical profile. Specifically, the molecular analysis distinguished patients with a longer disease duration, greater disease activity, radiographic damage and cardiovascular risk. WGCNA identified 11 highly co-expressed modules. Among them, six were differentially expressed between the two clusters, being responsible for the molecular and clinical distinction of those groups. The functional analysis of these 6 gene modules revealed the enrichment of these genes in pathways related to inflammation, oxidative metabolism, proliferation of B and T lymphocytes, immune response and the increase of cell survival. Finally, key genes were identified within each module (“hub genes”), whose expression was associated with a more active phenotype of the disease such as ALOX5, GAB2, PSMD13, CASP8, NOTCH e ITGA4.

Conclusion: 1) The whole transcriptomic analysis by RNAseq in peripheral mononuclear cells from axSpA patients distinguished, in an unsupervised manner, subgroups of patients with distinctive clinical profiles. 2)The analysis of gene modules identified new pathways and molecular functions potentially involved in the pathophysiology of the disease.


Disclosures: N. Barbarroja, None; L. Cuesta-Lopez, None; C. Pérez-Sánchez, None; A. Barberá-Betancourt, None; I. Arias-de la Rosa, None; M. Ruiz-Ponce, None; C. Lopez-Medina, None; I. Gómez-Garcia, None; l. Ladehesa-Pineda, None; M. Abalos-Aguilera, None; C. López-Pedrera, None; A. Escudero-Contreras, None; E. Collantes, None.

To cite this abstract in AMA style:

Barbarroja N, Cuesta-Lopez L, Pérez-Sánchez C, Barberá-Betancourt A, Arias-de la Rosa I, Ruiz-Ponce M, Lopez-Medina C, Gómez-Garcia I, Ladehesa-Pineda l, Abalos-Aguilera M, López-Pedrera C, Escudero-Contreras A, Collantes E. High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/high-throughput-transcriptomic-analysis-of-peripheral-mononuclear-cells-identifies-molecular-alterations-associated-with-the-active-clinical-phenotype-of-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-throughput-transcriptomic-analysis-of-peripheral-mononuclear-cells-identifies-molecular-alterations-associated-with-the-active-clinical-phenotype-of-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology